Magrolimab is a monoclonal antibody commercialized by Gilead Sciences, with a leading Phase II program in Marginal Zone B-cell Lymphoma. According to Globaldata, it is involved in 30 clinical trials, of which 6 were completed, 19 are ongoing, 4 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Magrolimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Magrolimab is expected to reach an annual total of $232 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Magrolimab Overview
Magrolimab is under development for the treatment of Hodgkin lymphoma., previously untreated, relapsed or refractory acute myelocytic leukemia and myelodysplastic syndrome, solid tumor, relapsed/refractory multiple myeloma, recurrent head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, urethral cancer, metastatic urothelial cancer, metastatic small cell lung cancer and metastatic non-small cell lung cancer, ureter cancer, breast cancer, colorectal cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, head and neck cancer, ovarian, AML, NHL, myelodysplastic syndrome, relapsed and refractory B-cell non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, triple negative breast cancer, indolent lymphoma, metastatic transitional (urothelial) tract cancer, bladder cancer, marginal zone or follicular lymphoma, malignant primary brain tumor, metastatic colorectal cancer and atherosclerosis. It is a humanized IgG4 subclass monoclonal antibody. The drug candidate is administered through intravenous route. It acts by targeting CD47.
It was also under development for cutaneous T-cell lymphoma.
Gilead Sciences Overview
Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer, and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.
The company reported revenues of (US Dollars) US$27,281 million for the fiscal year ended December 2022 (FY2022), a decrease of 0.1% over FY2021. In FY2022, the company’s operating margin was 26.9%, compared to an operating margin of 36.3% in FY2021. In FY2022, the company recorded a net margin of 16.8%, compared to a net margin of 22.8% in FY2021.
The company reported revenues of US$6,599 million for the second quarter ended June 2023, an increase of 3.9% over the previous quarter.
For a complete picture of Magrolimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
